[1]Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61(2):69-90.
[2]Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006,126(4):663-676.
[3]Spangler B, Kappelmann M, Schittek B, et al. ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma[J]. Int J Cancer, 2012,130(12):2801-2811.
[4]Kappelmann M, Bosserhoff A, Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma[J]. Eur J Cell Biol, 2014,93(1-2):76-81.
[5]Shaulian E. AP-1-The Jun proteins: oncogenes or tumor suppressors in disguise[J]? Cell Signal, 2010,22(6):894-899.
[6]Kuo KK, Lee KT, Chen KK, et al. Positive feedback loop of OCT4 and c-JUN expedites cancer stemness in liver cancer[J]. Stem Cells, 2016, doi: 10.1002/stem.2447.
[7]van Wenum M, Adam AA, Hakvoort TB, et al. Selecting cells for bioartificial liver devices and the importance of a 3D culture environment: A functional comparison between the HepaRG and C3A cell lines[J]. Int J Biol Sci, 2016,12(8):964-978.
[8]Han S, Guo J, Liu Y, et al. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation[J]. Oncotarget, 2015,6(42):44452-44465.
[9]Ulu?kan ?, Guinea-Viniegra J, Jimenez M, et al. Signalling in inflammatory skin disease by AP-1 (Fos/Jun)[J]. Clin Exp Rheumatol, 2015,33(4 Suppl 92):S44-49.
[10]Liu J, Han Q, Peng T, et al. The oncogene c-Jun impedes somatic cell reprogramming[J]. Nat Cell Biol, 2015,17(7):856-867.
[11]Zhou C, Yang X, Sun Y, et al. Comprehensive profiling reveals mechanisms of SOX2-mediated cell fate specification in human ESCs and NPCs[J]. Cell Res, 2016,26(2):171-189.
[12]Winiecka-Klimek M, Smolarz M, Walczak MP, et al. SOX2 and SOX2-MYC reprogramming process of fibroblasts to the neural stem cells compromised by senescence[J]. PLoS One, 2015,10(11):e0141688.
[13]Lundberg IV, Edin S, Ekl?f V, et al. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer[J]. BMC Cancer, 2016,16(1):471.
[14]Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma[J]. Nature, 2014,511(7508):246-250.
[15]Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic[J]. Clin Transl Med, 2014(1),3:19.
[16]Leis O, Eguiara A, Lopez-Arribillaga E, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells[J]. Oncogene, 2012,31(11):1354-1365.
[17]Nichols J, Smith A. Naive and primed pluripotent states[J]. Cell Stem Cell, 2009,4(6):487-492.
[18]Li M, Liu GH, Izpisua BJC. Navigating the epigenetic landscape of pluripotent stem cells[J]. Nat Rev Mol Cell Biol, 2012,13(8):524-535.
[19]Shan ZhY, Wu B, Zhang Y, et al. Generation of induced pluripotent stem cells derived from parthenogenetic embryonic stem cells and reprogramming of imprinted genes[J]. Acta Anatomica Sinica, 2015,46(4):553-557.(in Chinese)
单智焱, 武玢, 张玥, 等. 孤雌胚胎干细胞来源的诱导多能干细胞的建立及对印记基因表达的影响[J]. 解剖学报,2015,46(4):553-557.
[20]van den Hurk M, Kenis G, Bardy C, et al. Transcriptional and epigenetic mechanisms of cellular reprogramming to induced pluripotency[J]. Epigenomics, 2016,8(8):1131-1149.
[21]G1adych M, Andrzejewska A, Oleksiewicz U, et al. Epigenetic mechanisms of induced pluripotency[J]. Contemp Oncol (Pozn), 2015,19(1A):A30-38.
[22]Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation[J]. Cell, 2014, 156(4): 663-677.
[23]Guo Y, Liu S, Wang P, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas[J]. Histopathology, 2011, 59(4): 763-775.
[24]Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer[J]. Oncogene, 2010, 29(14): 2153-2159.
|